CONNECT WITH US

Tech

Biodimension secures Rs 8 Cr from IAN Angel Fund, others

Published on

Biodimension secures Rs 8 Cr from IAN Angel Fund, others

Bengaluru-based life sciences startup Biodimension has raised Rs 8 crore in a funding round led by IAN Angel Fund. Existing investor Campus Angels Network, Dr. Sampath Srisailam, and angel investor Aaryan Baid also participated in the round.

The proceeds will be used to accelerate product development, expand laboratory infrastructure, strengthen scientific and commercial teams, and support the commercialization of its products in India and overseas markets.

Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension develops biofabricated human tissue and organoid models as alternatives to animal testing for pharmaceutical, biotechnology, and cosmetic companies.

The startup's portfolio includes BioDEpi, BioDFT, BioDPigma, a Pan-Cancer Tumour Microenvironment (TME) Biobank, and Bioassay-as-a-Service (BaaS), which provide human-relevant testing solutions for research, safety assessment, and drug discovery.

Biodimension said it has established collaborations with pharmaceutical firms, biotech companies, research institutions, and contract research organizations across India and Singapore. The company plans to expand its oncology research offerings, scale its Bioassay-as-a-Service platform, and enter additional international markets, including Southeast Asia.



Source link
Related Topics:#Tech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Google Preferred Source